Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
Key points are not available for this paper at this time.
Abstract
Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas.
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol | Synapse